Literature DB >> 20675862

Giant Cell Tumor (tumor gigantocellularis, osteoclastoma) - epidemiology, diagnosis, treatment.

Marta Karpik1.   

Abstract

The author presents the epidemiology, classification, clinical features and strategies of treatment of Giant Cell Tumor. Giant Cell Tumor of Bone accounts for 4-8% of primary bone tumors. It is most commonly seen in women aged 20 to 40 years. The most common sites are the distal femur and proximal tibia, distal radius, and proximal humerus. Increasing pain at the tumor site is the most common presenting symptom. Three types of GCT can be distinguished radiographically according to the Cappanacci or Enneking classification. The mainstay of treatment is total mechanical removal with curettage. The recurrence rate is high (12-50%) during the first 2-3 years after surgery, regardless of pre-operative tumor stage. 5-7% cases of giant cell tumor produce malignant recurrences, usually after five to more than 10 years after surgery.

Entities:  

Mesh:

Year:  2010        PMID: 20675862

Source DB:  PubMed          Journal:  Ortop Traumatol Rehabil        ISSN: 1509-3492


  20 in total

1.  Histopathological, immunohistochemical, and image analytic parameters characterizing the stromal component in primary and recurrent giant cell tumor of bone.

Authors:  Charu Chandra Saxena; Rajni Safaya; Neha Kawatra Madan; Shah Alam Khan; Venkateswaran K Iyer
Journal:  J Clin Orthop Trauma       Date:  2015-10-26

Review 2.  Giant cell tumour of bone: a new evaluating system is necessary.

Authors:  Han Wang; Ningjun Wan; Yongcheng Hu
Journal:  Int Orthop       Date:  2012-10-05       Impact factor: 3.075

3.  Radiological and Histopathological Outcome of Giant Cell Tumor of Femur with Denosumab Treatment: A Case Report.

Authors:  Preethi Dileep Menon; R Krishnakumar; Annie Jojo
Journal:  J Clin Diagn Res       Date:  2016-12-01

4.  Smad3 is the key to transforming growth factor-β1-induced osteoclast differentiation in giant cell tumor of bone.

Authors:  Zhiyuan Lou; Yi Yang; Tingting Ren; Shun Tang; Xianbo Peng; Qunshan Lu; Yifeng Sun; Wei Guo
Journal:  Med Oncol       Date:  2013-05-21       Impact factor: 3.064

5.  MiR-125b inhibits stromal cell proliferation in giant cell tumor of bone by targeting parathyroid hormone 1 receptor.

Authors:  Pan-Feng Wu; Jie-Yu Liang; Fang Yu; Zheng-Bing Zhou; Ju-Yu Tang; Kang-Hua Li
Journal:  Iran J Basic Med Sci       Date:  2015-07       Impact factor: 2.699

6.  Differential Expression of ADAM23, CDKN2A (P16), MMP14 and VIM Associated with Giant Cell Tumor of Bone.

Authors:  André Luis Giacometti Conceição; Erica Babeto; Natalia Maria Candido; Fernanda Craveiro Franco; Débora Aparecida Pires de Campos Zuccari; Jane Lopes Bonilha; José Antônio Cordeiro; Marilia Freitas Calmon; Paula Rahal
Journal:  J Cancer       Date:  2015-05-23       Impact factor: 4.207

7.  Use of extended curettage with osteotomy and fenestration followed by reconstruction with conservation of muscle insertion in the treatment of Enneking stage II locally aggressive bone tumor of the proximal extremities: resection and treatment of bone tumors.

Authors:  Feiyan Chen; Jun Xia; Siqun Wang; Yibing Wei; Jianguo Wu; Gangyong Huang; Jie Chen; Jingsheng Shi
Journal:  World J Surg Oncol       Date:  2013-03-05       Impact factor: 2.754

8.  Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone.

Authors:  Yuki Yoshimatsu; Rei Noguchi; Ryuto Tsuchiya; Takuya Ono; Yooksil Sin; Sei Akane; Jun Sugaya; Tomoaki Mori; Suguru Fukushima; Akihiko Yoshida; Akira Kawai; Tadashi Kondo
Journal:  Hum Cell       Date:  2021-07-24       Impact factor: 4.374

9.  Surgical treatment for pelvic giant cell tumor: a multi-center study.

Authors:  Kai Zheng; Xiuchun Yu; Yongcheng Hu; Zhen Wang; Sujia Wu; Zhaoming Ye
Journal:  World J Surg Oncol       Date:  2016-04-05       Impact factor: 2.754

10.  The epidemiological and clinical features of primary giant cell tumor around the knee: A report from the multicenter retrospective study in china.

Authors:  Fengsong Lin; Yongcheng Hu; Liming Zhao; Huilin Zhang; Xiuchun Yu; Zhen Wang; Zhaoming Ye; Sujia Wu; Shibing Guo; Guochuan Zhang; Jinghua Wang
Journal:  J Bone Oncol       Date:  2016-02-11       Impact factor: 4.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.